Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.

A design strategy to convert a dual-binding site AChE inhibitor into triple functional compounds with promising in vitro profile against multifactorial syndromes, such as Alzheimer's disease, is proposed. The lead compound bis(7)-tacrine (2) was properly modified to confer to the new molecules the ability of chelating metals, involved in the neurodegenerative process. The multifunctional compounds show activity against human AChE, are able to inhibit the AChE-induced amyloid-beta aggregation, and chelate metals, such as iron and copper.

[1]  A. Beth,et al.  Bis(sulfo-N-succinimidyl) doxyl-2-spiro-5'-azelate: synthesis, characterization, and reaction with the anion-exchange channel in intact human erythrocytes. , 1989, Biochemistry.

[2]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[3]  H. Kozłowski,et al.  Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). , 2006, Chemical reviews.

[4]  P. Doraiswamy,et al.  Metals in our minds: therapeutic implications for neurodegenerative disorders , 2004, The Lancet Neurology.

[5]  A. Cavalli,et al.  Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors. , 2003, Farmaco.

[6]  R. Hider,et al.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy , 2005, British journal of pharmacology.

[7]  Maurizio Recanatini,et al.  A small molecule targeting the multifactorial nature of Alzheimer's disease. , 2007, Angewandte Chemie.

[8]  J. Sussman,et al.  Structure of a complex of the potent and specific inhibitor BW284C51 with Torpedo californica acetylcholinesterase. , 2002, Acta crystallographica. Section D, Biological crystallography.

[9]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[10]  L. Baum,et al.  Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. , 2004, Journal of Alzheimer's disease : JAD.

[11]  Andrea Cavalli,et al.  AClAP, Autonomous hierarchical agglomerative Cluster Analysis based protocol to partition conformational datasets , 2006, ISMB.

[12]  P. Carlier,et al.  Effects of bis(7)-tacrine, a novel anti-Alzheimer's agent, on rat brain AChE. , 1999, Neuroreport.

[13]  P. Carlier,et al.  Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions. , 1999, Journal of medicinal chemistry.

[14]  Y. Pang,et al.  A Potent and Selective Tacrine Analog—Biomembrane Permeation and Physicochemical Characterization , 2005, Pharmaceutical development and technology.

[15]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[16]  D. Dittmer,et al.  Models for the pyridine nucleotide coenzymes. Synthesis and properties of bridged dinicotinamide derivatives. , 1973, Journal of Organic Chemistry.

[17]  George Hsiao,et al.  Homodimeric tacrine congeners as acetylcholinesterase inhibitors. , 2002, Journal of medicinal chemistry.